JCXH-221

N/A

Report date: 2026/05/13 09:17:06

Base Information

Drug NameJCXH-221
Drug Alias NameJCXH-221JCXH-221 (mono-valent mRNA-LNP vaccine)JCXH-221 (mono-valent mRNA-LNP (lipid nanoparticle) vaccine)
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Communicable Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmorna (Hangzhou) Biotechnology Co., Ltd
China Registration ClassN/A

Develop Information

Active CompaniesImmorna Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Communicable Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A